 |
市場調查報告書
商品編碼
1907932
心肌缺血市場：依疾病類型、藥物類別、給藥途徑、藥物類型、最終用戶、通路和地區分類Myocardial Ischemia Market, By Disease Type, By Drug Class, By Route of Administration,By Drug Type, By End User, By Distribution Channel, By Geography |
||||||
2025 年心肌缺血市場規模預計為 47.2 億美元，預計到 2032 年將達到 79.8 億美元，2025 年至 2032 年的複合年成長率為 7.8%。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2024 | 市場規模（2025 年） | 47.2億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期（2025-2032 年）複合年成長率 | 7.80% | 預計金額（2032 年） | 79.8億美元 |
全球心肌缺血市場是心血管治療領域的重要組成部分，致力於解決全球主要的死亡和殘疾原因之一。心肌缺血的特徵是由於冠狀動脈阻塞或痙攣導致心肌血流減少，影響全球數百萬患者，其症狀涵蓋穩定性心絞痛到急性冠狀動脈症候群。該市場涵蓋多種治療手段，包括抗血小板藥物、 BETA阻斷劑、血管緊張素轉換酶抑制劑和他汀類藥物等藥物療法，以及經皮冠狀動脈介入治療（PCI）和冠狀動脈繞道手術手術（CABG）等先進治療性介入手術。
糖尿病、高血壓、肥胖和缺乏運動等心血管危險因子的日益普遍，以及全球人口老化，正顯著擴大目標患者群體。此外，診斷方法、藥物傳輸系統和微創手術技術的進步正在革新治療模式，推動市場成長。積極進行的研發活動，著眼於新型治療標靶、個人化醫療方法以及旨在改善治療效果並降低醫療成本的聯合治療，也對市場產生了積極影響。
市場動態
全球心肌缺血市場受多種關鍵因素驅動，這些因素持續影響其發展軌跡。主要成長要素歸因於全球心血管疾病負擔的日益加重，其中心肌缺血佔心臟相關住院和醫療保健支出的很大一部分。生活方式相關危險因子（例如糖尿病、高血壓、血脂異常症和吸煙）的日益普遍，尤其是在開發中國家，正在顯著擴大患者群體。
此外，診斷影像技術、生物標記檢測和治療性介入的技術進步提高了早期檢測和治療效果，從而推動了市場滲透。新型藥物製劑（包括緩釋性藥物和聯合治療）的開發提高了患者依從性和臨床療效。然而，該市場面臨一些可能阻礙其成長勢頭的重大限制因素。
高昂的治療費用，尤其是與高風險介入療法和慢性病藥物相關的費用，構成了重大障礙，尤其是在醫療資源匱乏的地區。醫療設備認證和藥物研發的嚴格監管架構導致核准時間長、研發成本高昂。此外，心血管疾病治療的複雜性，需要專業的知識和基礎設施，限制了其在醫療資源匱乏地區的市場滲透。重磅心血管藥物的專利到期加劇了學名藥，給現有企業的收入來源帶來了壓力。
儘管面臨這些挑戰，新興市場仍蘊藏著巨大的機會，這些市場的經濟成長和醫療基礎設施正在不斷改善。人們對預防心臟病學和風險分層的日益關注，為診斷和監測技術開闢了新的可能性。數位健康平台、遠端醫療和人工智慧（AI）應用的進步，可望改善患者管理並最佳化治療方案。
此外，基於基因分析和生物標記識別的個人化和精準醫療日益受到關注，這代表著一個很有前景的市場擴張新領域。
本報告的主要特點
- 本報告對全球心肌缺血市場進行了詳細分析，並給出了預測期（2025-2032 年）的市場規模和複合年成長率，以 2024 年為基準年。
- 它還重點介紹了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
- 它還提供了有關市場促進因素、限制因素和機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的關鍵見解。
- 全球心肌缺血市場的主要企業概況、產品系列、主要亮點、財務表現和策略等參數均已列出。
- 本報告提供的見解將使負責人和企業經營團隊能夠就未來的產品發布、合作關係、市場擴張和行銷策略做出明智的決策。
- 《全球心肌缺血市場》報告面向該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過各種用於分析全球心肌缺血市場的策略矩陣更輕鬆地做出決策。
目錄
第1章 分析目標與先決條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監理及趨勢分析
- 市場動態
- 促進要素
- 抑制因素
- 機會
- 影響分析
- 重大進展
- 監管情景
- 產品上市/核准
- PEST分析
- 波特五力分析
- 企業合併情景
- 產業趨勢
第4章 全球心肌缺血市場依疾病類型分類（2020-2032 年）
- 穩定性心絞痛
- 不穩定型心絞痛
- 無症狀性缺血
- 血管痙攣性（變異型）心絞痛
- 微血管缺血
5. 全球心肌缺血藥物市場（依藥物類別分類）（2020-2032 年）
- 抗心絞痛藥物（例如，硝酸甘油、單硝酸異山梨酯）
- 抗血小板藥物（例如，阿斯匹靈、Clopidogrel、替格瑞洛）
- 抗凝血劑（例如，肝素、依諾肝素、Apixaban）
- BETA阻斷劑（例如，美托洛爾、阿替洛爾、CARVEDILOL）
- ACE抑制劑（例如，Ramipril、Lisinopril、Enalapril）
- 血管收縮素II受體阻斷劑（例如，氯沙坦、Valsartan、Telmisartan）
- 鈣離子通道阻斷劑（例如，氨氯地平、地爾硫卓、維拉帕米）
- 硝酸鹽類藥物（例如，硝酸甘油噴霧、二硝酸吉尼）
- 他汀類藥物（例如，Atorvastatin、rosuvastatin、Simvastatin）
- 晚期鈉電流抑制劑/雷諾嗪（例如，雷諾嗪）
- 溶栓藥物（例如，Alteplase、Tenecteplase、鏈球菌激酶）
6. 全球心肌缺血治療市場依給藥途徑分類（2020-2032 年）
- 口服
- 腸外
7. 全球心肌缺血藥物市場（依藥物類型分類）（2020-2032 年）
- 品牌藥
- 非專利的
8. 全球心肌缺血市場（依最終用戶分類）（2020-2032 年）
- 醫院
- 心臟診所
- 診斷中心
- 門診手術中心
- 研究和學術機構
9. 全球心肌缺血市場依通路分類（2020-2032 年）
- 醫院藥房
- 零售藥房
- 網路藥房
第10章 全球心肌缺血市場區域分類（2020-2032 年）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第11章 競爭格局
- Pfizer Inc
- AstraZeneca PLC
- Bayer AG
- Novartis AG
- Merck and Co Inc
- Bristol-Myers Squibb Company
- Sanofi SA
- Daiichi Sankyo Company Limited
- Gilead Sciences Inc
- Johnson and Johnson
- Amgen Inc
- Boehringer Ingelheim
- Mylan NV
- Teva Pharmaceutical Industries Ltd
- GlaxoSmithKline PLC
第12章 分析師建議
- 機會
- 分析師觀點
- Coherent Opportunity Map (COM)
第13章 參考文獻與分析方法
- 參考
- 分析方法
- 關於 Coherent Market Insights
Myocardial Ischemia Market is estimated to be valued at USD 4.72 Bn in 2025 and is expected to reach USD 7.98 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.72 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.80% | 2032 Value Projection: | USD 7.98 Bn |
The global myocardial ischemia market represents a critical segment within the cardiovascular therapeutics landscape, addressing one of the leading causes of mortality and morbidity worldwide. Myocardial ischemia, characterized by reduced blood flow to the heart muscle due to coronary artery obstruction or spasm, affects millions of patients globally and encompasses conditions ranging from stable angina to acute coronary syndromes. The market encompasses diverse therapeutic interventions including pharmacological treatments such as antiplatelet agents, beta-blockers, ACE inhibitors, and statins, alongside advanced interventional procedures like percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG).
The increasing prevalence of cardiovascular risk factors including diabetes, hypertension, obesity, and sedentary lifestyles, coupled with an aging global population, has significantly expanded the addressable patient population. Furthermore, technological advancements in diagnostic modalities, drug delivery systems, and minimally invasive surgical techniques have revolutionized treatment paradigms, driving market growth. The market also benefits from robust research and development activities focused on novel therapeutic targets, personalized medicine approaches, and combination therapies that improve patient outcomes while reducing healthcare costs.
Market Dynamics
The global myocardial ischemia market is propelled by several key drivers that continue to shape its trajectory. The primary growth driver stems from the escalating global burden of cardiovascular diseases, with myocardial ischemia representing a significant portion of cardiac-related hospitalizations and healthcare expenditures. Rising prevalence of lifestyle-associated risk factors including diabetes mellitus, hypertension, dyslipidemia, and smoking, particularly in developing economies, has expanded the patient pool substantially.
Additionally, technological innovations in diagnostic imaging, biomarker detection, and therapeutic interventions have enhanced early detection and treatment efficacy, driving market adoption. The development of novel drug formulations, including extended-release medications and combination therapies, has improved patient compliance and clinical outcomes. However, the market faces notable restraints that could impede growth momentum.
High treatment costs associated with advanced interventional procedures and chronic medication regimens pose significant barriers, particularly in resource-constrained healthcare systems. Stringent regulatory frameworks governing medical device approvals and pharmaceutical development create lengthy approval timelines and substantial development costs. Additionally, the complexity of cardiovascular care requiring specialized expertise and infrastructure limits market penetration in underserved regions. Patent expirations of blockbuster cardiovascular medications have intensified generic competition, pressuring revenue streams for established players.
Despite these challenges, substantial opportunities exist within emerging markets experiencing economic growth and healthcare infrastructure development. The increasing focus on preventive cardiology and risk stratification presents opportunities for diagnostic and monitoring technologies. Advances in digital health platforms, telemedicine, and artificial intelligence applications offer potential for improving patient management and treatment optimization.
Furthermore, the growing emphasis on personalized medicine and precision therapeutics based on genetic profiling and biomarker identification represents a promising frontier for market expansion.
Key Features of the Study
- This report provides in-depth analysis of the global myocardial ischemia market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global myocardial ischemia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc, AstraZeneca PLC, Bayer AG, Novartis AG, Merck and Co Inc, Bristol-Myers Squibb Company, Sanofi SA, Daiichi Sankyo Company Limited, Gilead Sciences Inc, Johnson and Johnson, Amgen Inc, Boehringer Ingelheim, Mylan NV, Teva Pharmaceutical Industries Ltd, and GlaxoSmithKline PLC
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global myocardial ischemia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myocardial ischemia market
Market Segmentation
- Disease Type Insights (Revenue, USD Bn, 2020 - 2032)
- Stable Angina
- Unstable Angina
- Silent Myocardial Ischemia
- Vasospastic (Prinzmetal) Angina
- Microvascular Ischemia
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Anti-Anginal Agents (e.g., nitroglycerin, isosorbide mononitrate)
- Antiplatelet Agents (e.g., aspirin, clopidogrel, ticagrelor)
- Anticoagulants (e.g., heparin, enoxaparin, apixaban)
- Beta-Blockers (e.g., metoprolol, atenolol, carvedilol)
- ACE Inhibitors (e.g., ramipril, lisinopril, enalapril)
- Angiotensin II Receptor Blockers (e.g., losartan, valsartan, telmisartan)
- Calcium Channel Blockers (e.g., amlodipine, diltiazem, verapamil)
- Nitrates (e.g., nitroglycerin spray, isosorbide dinitrate)
- Statins (e.g., atorvastatin, rosuvastatin, simvastatin)
- Late Sodium Current Inhibitors/Ranolazine (e.g., ranolazine)
- Thrombolytics (e.g., alteplase, tenecteplase, streptokinase)
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Cardiac Specialty Clinics
- Diagnostic Centers
- Ambulatory Surgical Centers
- Research and Academic Institutes
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc
- AstraZeneca PLC
- Bayer AG
- Novartis AG
- Merck and Co Inc
- Bristol-Myers Squibb Company
- Sanofi SA
- Daiichi Sankyo Company Limited
- Gilead Sciences Inc
- Johnson and Johnson
- Amgen Inc
- Boehringer Ingelheim
- Mylan NV
- Teva Pharmaceutical Industries Ltd
- GlaxoSmithKline PLC
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Myocardial Ischemia Market, By Disease Type
- Global Myocardial Ischemia Market, By Drug Class
- Global Myocardial Ischemia Market, By Route of Administration
- Global Myocardial Ischemia Market, By Drug Type
- Global Myocardial Ischemia Market, By End User
- Global Myocardial Ischemia Market, By Distribution Channel
- Global Myocardial Ischemia Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Myocardial Ischemia Market, By Disease Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Stable Angina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Unstable Angina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Silent Myocardial Ischemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Vasospastic (Prinzmetal) Angina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Microvascular Ischemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Myocardial Ischemia Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Anti-Anginal Agents (e.g., nitroglycerin, isosorbide mononitrate)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antiplatelet Agents (e.g., aspirin, clopidogrel, ticagrelor)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Anticoagulants (e.g., heparin, enoxaparin, apixaban)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Beta-Blockers (e.g., metoprolol, atenolol, carvedilol)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- ACE Inhibitors (e.g., ramipril, lisinopril, enalapril)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Angiotensin II Receptor Blockers (e.g., losartan, valsartan, telmisartan)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Calcium Channel Blockers (e.g., amlodipine, diltiazem, verapamil)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Nitrates (e.g., nitroglycerin spray, isosorbide dinitrate)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Statins (e.g., atorvastatin, rosuvastatin, simvastatin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Late Sodium Current Inhibitors/Ranolazine (e.g., ranolazine)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Thrombolytics (e.g., alteplase, tenecteplase, streptokinase)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Myocardial Ischemia Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Myocardial Ischemia Market, By Drug Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Myocardial Ischemia Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cardiac Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diagnostic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Research and Academic Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Myocardial Ischemia Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Myocardial Ischemia Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck and Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson and Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
擴大性心肌病治療市場依治療分類、治療方法、給藥途徑、最終用戶和分銷管道分類－2025-2032年全球預測
犬擴張型心肌病(DCM)治療藥的全球市場:治療方法，各給藥途徑，各流通管道，各地區，機會，預測，2018年～2032年
心肌炎治療市場（藥物類別：正性肌力藥物、BETA-腎上腺素能藥物、利尿劑、皮質類固醇等；給藥途徑：口服和靜脈注射）- 全球產業分析、規模、佔有率、成長、趨勢和預測，2024-2034 年
長 QT 症候群治療市場 - 按類型（1 型、2 型、3 型）、治療（藥物、手術）、診斷（測試、心電圖、基因測試）、全球預測（2024 年 - 2032 年）